Stress and trauma are not causes of breast cancer, research rules 
July 25, 2016
Why Geographic Cancer Clusters Are Impossible to Prove
July 26, 2016
Show all

Closer Look at ICER, Group Now Evaluating RRMS Therapies

Therapies for the relapsing-remitting form of multiple sclerosis are evaluated by experts.

The Institute of Clinical and Economic Review (ICER), the nonprofit organization that released a preliminary draft last week intended to shape the Institute’s forthcoming report on the effectiveness and benefits of therapies for relapsing-remitting multiple sclerosis (RRMS), is made up of experts in healthcare policy from across the U.S. who, through the group’s Advisory Boards, offer strategic advice on major health topics and treatments.

Specifically, ICER conducts analyses on treatment effectiveness and costs, and develops reports using methods that make it easier to translate evidence into decisions. The Institute says the preliminary ‘scoping document,’ titled “Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Effectiveness and Value, Draft Background and Scope,” was developed with extensive input from several stakeholders, including multiple sclerosis (MS) patient advocacy organizations.

ICER’s research process encourages inclusion of a broad range of disease-modifying therapies, and the scoping document is available for public scrutiny. ‘Scoping’ is the term used by ICER to describe the process of refining a research topic and defining key questions that will form the basis of both the evidence review and the panel’s deliberations during in-person meetings, supporting the goal of getting effective, safe drugs to market quickly at a price affordable to patients and the health system, without hindering new drug development.

Read Full Article: Closer Look at ICER, Group Now Evaluating RRMS Therapies

Read Full Article: Closer Look at ICER, Group Now Evaluating RRMS Therapies

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.